IL259424B - Nitrogen-substituted indole derivatives as pge2 receptor modulators - Google Patents
Nitrogen-substituted indole derivatives as pge2 receptor modulatorsInfo
- Publication number
- IL259424B IL259424B IL259424A IL25942418A IL259424B IL 259424 B IL259424 B IL 259424B IL 259424 A IL259424 A IL 259424A IL 25942418 A IL25942418 A IL 25942418A IL 259424 B IL259424 B IL 259424B
- Authority
- IL
- Israel
- Prior art keywords
- receptor modulators
- indole derivatives
- substituted indole
- pge2 receptor
- pge2
- Prior art date
Links
- -1 N-substituted indole Chemical class 0.000 title 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 title 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015077269 | 2015-11-20 | ||
| PCT/EP2016/078028 WO2017085198A1 (en) | 2015-11-20 | 2016-11-17 | N-substituted indole derivatives as pge2 receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL259424A IL259424A (en) | 2018-07-31 |
| IL259424B true IL259424B (en) | 2020-11-30 |
Family
ID=57326428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259424A IL259424B (en) | 2015-11-20 | 2018-05-16 | Nitrogen-substituted indole derivatives as pge2 receptor modulators |
Country Status (34)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US12018000B2 (en) | 2017-03-27 | 2024-06-25 | HYDRO-QUéBEC | Lithium salts of cyano-substituted imidazole for lithium ion batteries |
| KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| CN109678780A (zh) * | 2017-10-19 | 2019-04-26 | 中国石油化工股份有限公司 | 一种制备3-烷基吲哚衍生物的方法 |
| JP2021503486A (ja) | 2017-11-20 | 2021-02-12 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物ならびに組成物および使用法 |
| AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| WO2020142486A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3693359A1 (en) | 2019-02-08 | 2020-08-12 | Medibiofarma, S.L. | New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators |
| WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト |
| AU2020379734B2 (en) | 2019-11-04 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117683049A (zh) | 2020-09-15 | 2024-03-12 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| EP4359399A4 (en) | 2021-06-24 | 2025-04-23 | Reservoir Neuroscience, Inc. | EP2 antagonist compounds |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| EP1267867B1 (en) | 2000-03-24 | 2008-05-14 | Asterand Uk Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
| CA2482382A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| EP1506220A1 (en) | 2002-05-23 | 2005-02-16 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| DE602004013938D1 (de) | 2003-01-29 | 2008-07-03 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| PE20050347A1 (es) | 2003-08-26 | 2005-05-04 | Teijin Pharma Ltd | Derivados de pirrolopirimidina |
| AU2004268839A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
| ES2327760T3 (es) | 2004-05-04 | 2009-11-03 | Raqualia Pharma Inc | Compuestos de aril-heteroaril-amida ortosustituidos. |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| US8013159B2 (en) | 2005-05-19 | 2011-09-06 | Merck Canada Inc. | Quinoline derivatives as EP4 antagonists |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| DOP2007000068A (es) | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| EP2044056B1 (en) * | 2006-07-14 | 2012-08-22 | Novartis AG | Pyrimidine derivatives as alk-5 inhibitors |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| JP5301469B2 (ja) | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
| CA2681861A1 (en) | 2007-03-26 | 2008-10-16 | Astellas Pharma Inc. | Ornithine derivative |
| AU2008232265B2 (en) | 2007-03-26 | 2013-02-28 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| HRP20110470T1 (hr) | 2007-10-12 | 2011-07-31 | Ingenium Pharmaceuticals Gmbh | Inhibitori proteinskih kinaza |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| DK2565191T3 (da) | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
| US9029414B2 (en) | 2008-09-19 | 2015-05-12 | Biotechnology Research Corporation | Triterpenoid compounds and methods of use thereof |
| MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| EP2504008A1 (en) | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
| RU2528386C2 (ru) | 2010-05-21 | 2014-09-20 | Кемилиа Аб | Новые производные пиримидина |
| JP5956448B2 (ja) | 2010-09-21 | 2016-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| US9175080B2 (en) | 2010-09-29 | 2015-11-03 | Nb Health Laboratory Co., Ltd. | Antibody against human prostaglandin E2 receptor EP4 |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| BR112013012380A2 (pt) | 2010-11-17 | 2016-08-30 | Novartis Ag | compostos 3-(aminoaril)-piridina |
| US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| DK2688883T3 (en) * | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| EP2702043A1 (en) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| WO2012177618A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| DK2729445T3 (en) | 2011-07-04 | 2016-01-18 | Rottapharm Biotech Srl | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| LT2841428T (lt) | 2012-04-24 | 2018-12-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (en) * | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| WO2014084778A1 (en) | 2012-11-27 | 2014-06-05 | Thomas Helledays Stiftelse För Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| LT3009426T (lt) | 2013-06-12 | 2018-07-25 | Kaken Pharmaceutical Co., Ltd. | 4-alkinilimidazolo darinys ir jį, kaip veiklųjį ingredientą, apimantis vaistas |
| CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| HUE048874T2 (hu) | 2013-09-06 | 2020-08-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazol-származékok, mint immunmodulátorok |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| WO2015058031A1 (en) | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| SI3083562T1 (sl) | 2013-12-17 | 2017-11-30 | Eli Lilly And Company | Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja |
| EA028675B1 (ru) | 2013-12-17 | 2017-12-29 | Эли Лилли Энд Компани | Соединения диметилбензойной кислоты |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| WO2015179615A1 (en) | 2014-05-23 | 2015-11-26 | Eisai R&D Management Co., Ltd | Combination therapies for the treatment of cancer |
| US10064869B2 (en) | 2014-06-04 | 2018-09-04 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| EP3778562A1 (en) | 2015-01-09 | 2021-02-17 | ONO Pharmaceutical Co., Ltd. | Tricyclic spiro compound |
| CN108368127B (zh) | 2015-07-23 | 2020-12-11 | 武田药品工业株式会社 | 化合物及其作为ep4受体拮抗剂的用途 |
| CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| CR20180323A (es) * | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN109863143B (zh) | 2016-07-13 | 2021-10-15 | 威泰克斯制药公司 | 提高基因组编辑效率的方法、组合物和试剂盒 |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
-
2015
- 2015-11-20 CR CR20180323A patent/CR20180323A/es unknown
-
2016
- 2016-11-17 EA EA201891179A patent/EA037953B1/ru unknown
- 2016-11-17 PT PT211868310T patent/PT3928836T/pt unknown
- 2016-11-17 UA UAA201806812A patent/UA123441C2/uk unknown
- 2016-11-17 WO PCT/EP2016/078028 patent/WO2017085198A1/en not_active Ceased
- 2016-11-17 PL PL21186831.0T patent/PL3928836T3/pl unknown
- 2016-11-17 LT LTEPPCT/EP2016/078028T patent/LT3377483T/lt unknown
- 2016-11-17 RS RS20241254A patent/RS66179B1/sr unknown
- 2016-11-17 HR HRP20211678TT patent/HRP20211678T1/hr unknown
- 2016-11-17 PT PT167975770T patent/PT3377483T/pt unknown
- 2016-11-17 HR HRP20241521TT patent/HRP20241521T1/hr unknown
- 2016-11-17 CA CA3002610A patent/CA3002610C/en active Active
- 2016-11-17 CN CN201680066933.8A patent/CN108349949B/zh active Active
- 2016-11-17 MX MX2018005268A patent/MX375978B/es active IP Right Grant
- 2016-11-17 DK DK21186831.0T patent/DK3928836T3/da active
- 2016-11-17 US US15/777,597 patent/US11241431B2/en active Active
- 2016-11-17 JP JP2018526184A patent/JP2018534328A/ja not_active Ceased
- 2016-11-17 ES ES21186831T patent/ES2994636T3/es active Active
- 2016-11-17 SI SI201631863T patent/SI3928836T1/sl unknown
- 2016-11-17 RS RS20211424A patent/RS62598B1/sr unknown
- 2016-11-17 PE PE2018000994A patent/PE20181304A1/es unknown
- 2016-11-17 MA MA43251A patent/MA43251B1/fr unknown
- 2016-11-17 FI FIEP21186831.0T patent/FI3928836T3/fi active
- 2016-11-17 HU HUE21186831A patent/HUE069520T2/hu unknown
- 2016-11-17 AU AU2016358242A patent/AU2016358242B2/en active Active
- 2016-11-17 EP EP21186831.0A patent/EP3928836B1/en active Active
- 2016-11-17 BR BR112018010291-1A patent/BR112018010291B1/pt active IP Right Grant
- 2016-11-17 LT LTEP21186831.0T patent/LT3928836T/lt unknown
- 2016-11-17 PL PL16797577T patent/PL3377483T3/pl unknown
- 2016-11-17 EP EP16797577.0A patent/EP3377483B9/en active Active
- 2016-11-17 ES ES16797577T patent/ES2897954T3/es active Active
- 2016-11-17 KR KR1020187017474A patent/KR102352022B1/ko active Active
- 2016-11-17 MY MYPI2018701873A patent/MY195888A/en unknown
- 2016-11-17 HU HUE16797577A patent/HUE056679T2/hu unknown
- 2016-11-17 SG SG11201803627XA patent/SG11201803627XA/en unknown
- 2016-11-17 MA MA55046A patent/MA55046B1/fr unknown
- 2016-11-17 DK DK16797577.0T patent/DK3377483T3/da active
- 2016-11-17 SI SI201631400T patent/SI3377483T1/sl unknown
- 2016-11-18 TW TW109133855A patent/TWI754397B/zh active
- 2016-11-18 TW TW105137938A patent/TWI719078B/zh active
-
2018
- 2018-05-15 SA SA518391588A patent/SA518391588B1/ar unknown
- 2018-05-16 IL IL259424A patent/IL259424B/en active IP Right Grant
- 2018-05-17 CL CL2018001325A patent/CL2018001325A1/es unknown
- 2018-05-18 PH PH12018501077A patent/PH12018501077B1/en unknown
- 2018-05-30 CO CONC2018/0005715A patent/CO2018005715A2/es unknown
-
2021
- 2021-04-13 JP JP2021067831A patent/JP7228618B2/ja active Active
- 2021-11-30 CY CY20211101035T patent/CY1124913T1/el unknown
- 2021-12-13 US US17/549,828 patent/US12011444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259424B (en) | Nitrogen-substituted indole derivatives as pge2 receptor modulators | |
| IL270620A (en) | Pyrimidine history as PGE2 receptor modulators | |
| HUE056080T2 (hu) | Fenilszármazékok mint PGE2 receptor modulátorok | |
| IL270616B (en) | Nitrogen-substituted indoles | |
| IL249267A0 (en) | Materials containing carbonitrile and their use for selective modulation of the androgen receptor | |
| IL253411A0 (en) | History of hydroxyalkylpiperazine as cxcr3 receptor modulators | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| IL257869A (en) | Fluoroindole derivatives as positive allosteric modulators for muscarinic receptor am.1 | |
| IL254711A0 (en) | History of Indole | |
| HK1260563A1 (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| ZA201908398B (en) | N-substituted indole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |